How TREMFYA® works
How to take TREMFYA®
Start and stay on TREMFYA®
Explore TREMFYA®
In a trial of patients who received TREMFYA® subcutaneously for initial and maintenance doses:
FAST ACTING
12 weeks
~3 out of 10 patients achieved endoscopic response at 12 weeks.†
~5 out of 10 patients achieved clinical remission.
Decreases in abdominal pain and
stool frequency were observed as early as 4 weeks.
LONG LASTING
1 year
~6 out of 10 patients achieved clinical remission.
Clinical remission means remission of symptoms.
SOME
PATIENTS SAW
VISIBLE
HEALING
OF THE INTESTINAL LINING†
~3 out of 10 patients were in endoscopic remission† at 1 year.
†Endoscopic remission and endoscopic response are based on areas visualized on colonoscopy, which may not represent the deeper bowel layer or entire GI tract.
AT 2 YEARS
~5 out of 10 patients were in clinical remission.‡
‡After 1 year, patients and healthcare providers knew that TREMFYA® was used. This may have increased results.
Results may vary.
Ask your healthcare provider if TREMFYA® is right for you.
TREMFYA® is the only IL-23 blocker for CD to offer self-administration from the start
You and your healthcare provider will discuss how you start TREMFYA® for CD:
Subcutaneous (SC) injections under the skin following training*
OR
Intravenous (IV) infusions
through a vein in the arm
*If your healthcare provider decides that you or a caregiver may be able to give your injections at home,
you should receive training on the right way to prepare and inject before attempting to inject yourself.
CD=Crohn’s disease; IL=interleukin.
JUST PRESCRIBED
TREMFYA®?
Get the most out of your
treatment journey with
personalized support.
TREMFYA withMe
Savings Program
Pay as little as $0 per dose
For eligible patients using commercial
insurance. Maximum
program benefit per
calendar year applies. Offer subject
to
change
or end without notice. See
program
requirements at
TREMFYAwithMeSavings.com.